1-4 of 4
Katherine P. Hearn, BSN, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation

May Daher, MD, Juliana Elisa Hidalgo Lopez, MD, Jasleen K. Randhawa, MD, Kausar Jabeen Jabbar, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Katherine P. Hearn, BSN, RN, Steven R. Reyes, MS, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2016) 128 (22): 3191.
https://doi.org/10.1182/blood.V128.22.3191.3191
Published: 2016
Journal Articles

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney D DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Pierre Fenaux, MD PhD, Michael E. Petrone, MD MPH, Patrick Simon Zbyszewski, MBA, Steven M. Fruchtman, MD, Lewis R. Silverman, MD
Journal: Blood
Blood (2016) 128 (22): 3167.
https://doi.org/10.1182/blood.V128.22.3167.3167
Published: 2016
Journal Articles

A Clinical Study of OPN-305, a Toll-like Receptor 2 (TLR-2) Antibody, in Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received Prior Hypomethylating Agent (HMA) Therapy

Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD, Hui Yang, MD PhD, Yue Wei, PhD, Yesid Alvarado, MD, Courtney D. DiNardo, MD MSCE, Naval G. Daver, MD, Marina Konopleva, MD PhD, Katherine P. Hearn, BSN, RN, Robert Miller, Sarah Arbe-Barnes, Peter Mc Guirk, Tara Kearney, Brian Keogh, Hagop M. Kantarjian, MD, Mary Reilly
Journal: Blood
Blood (2016) 128 (22): 227.
https://doi.org/10.1182/blood.V128.22.227.227
Published: 2016
Journal Articles

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS)

Shyamala C. Navada, MD, Lewis R. Silverman, MD, Katherine P. Hearn, BSN, RN, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, CCRN, Yesid Alvarado, MD, Naval Daver, MD, Courtney DiNardo, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Tapan Kadia, MD, Pierre Fenaux, MD PhD, Steve Fruchtman, MD, Nozar Azarnia, PhD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2015) 126 (23): 910.
https://doi.org/10.1182/blood.V126.23.910.910
Published: 2015